drugset / Trial / NCT02966964
A Clinical Trials to Evaluate the Efficacy and Safety of Tenofovir With and Without DWPUR001 in Patients With HBV
RandomizedParallel-groupDouble-blindTreatment
Summary
The patient who meets the inclusion/exclusion criteria is assigned to Test1 group or Test 2 group or control group randomly. All subjects take one pill of Viread® Tab. (Tenofovir Disoproxil Fumarate 300mg) once a day for 48 weeks. At the same time, all randomized subjects take two pills of DWPUR001 or Placebo of DWPUR001 twice a day for 48 weeks.
Timeline
- Start
- 2015-04
- Primary completion
- 2018-11
- Completion
- 2019-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DWPUR001 | Unknown | 300 mg | Oral |
| Subject | DWPUR001 | Unknown | 500 mg | Oral |